Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOT

Authors:
  • JSJennifer Scodes
    Jennifer Scodes
  • MPMartina Pavlicova
    Martina Pavlicova
  • TCTse-Hwei Ma Choo
    Tse-Hwei Ma Choo
  • MGManesh Gopaldas
    Manesh Gopaldas
  • AHAngela Haeny
    Angela Haeny
  • OOOnumara Opara
    Onumara Opara
  • TRTaeho Greg Rhee
    Taeho Greg Rhee
  • JRJohn Rotrosen
    John Rotrosen
  • ENEdward V. Jr Nunes
    Edward V. Jr Nunes
  • KHKathryn Hawk
    Kathryn Hawk
  • EEE. Jennifer Edelman
    E. Jennifer Edelman

Abstract
Objective: We sought to identify the sociodemographic and clinical characteristics associated with homelessnesss, and explore the relationship between homelessnesss and treatment outcomes among Black individuals. Methods: This is a secondary analysis of the subgroup of Black participants (n = 73) enrolled in “X:BOT,” a 24-week multisite randomized clinical trial comparing the effectiveness of extended-release naltrexone versus sublingual buprenorphine-naloxone (n = 570). Outcomes included medication initiation, return to extramedical use of opioids assessed by both self-report and urine toxicology, and engagement in medications for opioid use disorder (MOUD) treatment at 28 weeks postrandomization. Descriptive statistics were performed. Results: Black participants were mostly unmarried and male, and about a third were aged 21–30 years. Among people experiencing homelessnesss, more were uninsured (45.5% [10/22] vs 19.6% [10/51]), unemployed (77.3% [17/22] vs 64.7% [33/51]), and reported alcohol (40.9% [9/22] vs 23.5% [12/51]) and sedative use (54.5% [12/22] vs 17.6% [9/51]) within the previous 30 days. Compared with housed Black individuals, a slightly higher proportion of Black individuals experiencing homelessnesss successfully initiated study medication (81.1% [18/22] vs 72.6% [37/51]); similar proportions returned to opioid use during the trial (68.2% [15/22] vs 68.6% [35/51]) and were engaged in MOUD at 28 weeks after trial entry (72.2% [13/18] vs 69.7% [23/33]) among participants located for follow-up. Conclusions: These descriptive results among Black patients participating in a trial of MOUD suggest that efficacious MOUD is possible despite homelessnesss with additional clinical supports such as those provided by a clinical trial.

This publication has 11 references indexed in Scilit: